Idorsia Japan Set to File Its 2nd and 3rd Drugs Early Next Year, Eyes 80 Billion Yen Sales in 5 Years

Idorsia Japan President Satoshi Tanaka Swiss drug maker Idorsia Pharmaceuticals made its foray into the Japanese market with the launch of Pivlaz (clazosentan sodium) in April. Now, it is poised to enrich its offering by filing two more products in...read more